Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: Immunoprecise Antibodies Ltd

Market Cap 11Cr 7.95Cr 6.9Cr 6.36Cr 5.96Cr 761.53Cr 11Cr 76Cr 29Cr 367.08Cr 30Cr 29Cr 1.28TCr P/E Ratio 2026 *
-7.19x
P/E Ratio 2027 * -8.63x
Enterprise Value 11Cr 7.95Cr 6.9Cr 6.36Cr 5.96Cr 761.53Cr 11Cr 76Cr 29Cr 367.08Cr 30Cr 29Cr 1.28TCr EV / Sales 2026 *
7.02x
EV / Sales 2027 * 5.44x
Free-Float
90.98%
Yield 2026 *
-
Yield 2027 * -
10/06 MindWalk Holdings Corp. Launches ReefIQ, a Biological Context Layer for AI Drug Discovery CI
02/06 MindWalk's Preclinical Dengue Data Support a HYFT® Computational Prediction: Immunogens Designed on the Predicted Target Elicited Cross-Reactive Antibodies Against Antigens of All Four Dengue Serotypes, Reproduced Across Two Independent Campaigns CI
27/05 Mindwalk Holdings Corp. Launches Pandemic Response Platform Via Hyft Technology CI
12/03 MindWalk Holdings Corp., Q3 2026 Earnings Call, Mar 12, 2026
12/03 MindWalk Holdings Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2026 CI
07/03 MindWalk announces B cell llama™, a nanobody discovery platform designed for the bispecific and cell therapy era RE
07/03 MindWalk Holdings Corp Announces B Cell Llama Nanobody Discovery Platform CI
27/01 MindWalk Holdings Corp. Applies HYFT Technology to Detect Functional Adjacency Linked to Portfolio Risk in AI-Designed Therapeutics CI
14/01 Mindwalk Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic Tdp-43 in Neurodegenerative Disease CI
14/01 Mindwalk Holdings Corp. Validates Platform Precision with Breakthrough Discovery Targeting Pathogenic Tdp-43 in Neurodegenerative Disease CI
10/01 MindWalk Holdings Corp. Advances Universal Influenza Program with A Breakthrough Functional Insight CI
15/12 MindWalk Holdings Corp., Q2 2026 Earnings Call, Dec 15, 2025
15/12 MindWalk Holdings Corp. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2025 CI
Manager TitleAgeSince
Chief Executive Officer - 21/02/2018
Director of Finance/CFO 62 20/10/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 24/05/2018
Chairman - -
Director/Board Member 57 07/07/2025
Change 5-day change 1-year change 3-year change Capi.($)
-6.29%-23.22% - - 8Cr
+2.34%-2.51%+18.20%-18.71% 6.12TCr
+2.50%+4.43%+64.44%+218.90% 5.82TCr
-0.92%+28.60%+28.60%+28.60% 3.95TCr
+4.16%+16.25%-56.08%-64.88% 3.51TCr
+2.92%+1.01%+49.13%-36.69% 2.87TCr
+3.84%+7.12%+57.52%+74.64% 2.11TCr
+5.15%-7.58%+71.82%-61.40% 1.82TCr
-1.88%-5.07%-10.05%+93.76% 1.65TCr
+0.78%-1.57%+44.59%+101.10% 1.59TCr
Average +1.24%+1.25%+29.80%+37.26% 3.27TCr
Weighted average by Cap. +2.16%+1.44%+28.87%+44.13%

Financials

2026 *2027 *
Net sales 1.59Cr 1.13Cr 98.38L 90.68L 84.97L 108.55Cr 1.62Cr 11Cr 4.19Cr 52Cr 4.26Cr 4.16Cr 181.93Cr 2.05Cr 1.46Cr 1.27Cr 1.17Cr 1.1Cr 139.96Cr 2.09Cr 14Cr 5.4Cr 67Cr 5.49Cr 5.37Cr 234.57Cr
Net income -1.43Cr -1.02Cr -88.55L -81.62L -76.48L -98Cr -1.46Cr -9.74Cr -3.77Cr -47Cr -3.83Cr -3.75Cr -163.75Cr -1.2Cr -85.71L -74.38L -68.56L -64.24L -82Cr -1.23Cr -8.18Cr -3.17Cr -40Cr -3.22Cr -3.15Cr -137.55Cr
Net Debt - -
Logo Immunoprecise Antibodies Ltd
MindWalk Holdings Corp., formerly ImmunoPrecise Antibodies Ltd., is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, the Company unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!